Plasma Homocysteine and Risk for Congestive Heart Failure in Adults Without Prior Myocardial Infarction

JAMA

Volumn 289, Issue 10, 2003, Pages 1251-1257

  Vasan, Ramachandran S ^a,f   Beiser, Alexa ^a   D'Agostino, Ralph B ^a,b   Levy, Daniel ^a,c,d   Selhub, Jacob ^e   Jacques, Paul F ^e   Rosenberg, Irwin H ^e   Wilson, Peter W F ^a  

^a FRAMINGHAM HEART STUDY   (United States)

^b USA   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e TUFTS UNIVERSITY   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HOMOCYSTEINE BLOOD LEVEL; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; BLOOD; ECHOGRAPHY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE, CONGESTIVE; HOMOCYSTEINE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037433466     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.10.1251     Document Type: Article

References (41)

1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2000:19-20, 31.
2. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure. Eur Heart J. 1998;19(suppl P):P9-P16.
3. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J. 1997;18:208-225.
4. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
5. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men. J Intern Med. 2001;249:253-261.
6. Kenchalah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-313.
7. Bostom AG, Selhub J. Homocysteine and arteriosclerosis. Circulation. 1999;99:2361-2363.
8. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease. Ann Intern Med. 1999;131:363-375.
9. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31-62.
10. Cooke GE, Eaton GM, Whitby G, et al. Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients. J Am Coll Cardiol. 2000;36:509-516.
11. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. Metabolism. 2001;50:1466-1471.
12. Chen P, Poddar R, Tipa EV, et al. Homocysteine metabolism in cardiovascular cells and tissues. Adv Enzyme Reg. 1999;39:93-109.
13. Loscalzo J. The oxidant stress of hyperhomocyst (e)inemia. J Clin Invest. 1996;98:5-7.
14. Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens. 2002;15:157-163.
15. Blacher J, Demuth K, Guerin AP, et al. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol. 1999;12:248-255.
16. Dawber TR, Meadors GF, Moore FE. Epidemiologic approaches to heart disease: the Framingham Study. Am J Public Health. 1951;41:279-286.
17. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
18. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, I. Diabet Med. 1998;15:539-553.
19. Kannel WB, Wolf PA, Garrison RJ, eds. Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death in Pooled Repeated Biennial Measurements: Framingham Heart Study, 30 Year Follow-up. Bethesda, Md: US Dept of Health and Human Services; 1987. Section 34.
20. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43-52.
21. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
22. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum. Clin Chem. 1993;39:1764-1779.
23. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure. N Engl J Med. 1971;285:1441-1446.
24. Mosterd A, Deckers JW, Hoes AW, et al. Classification of heart failure in population based research. Eur J Epidemiol. 1997;13:491-502.
25. Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972;34(series B):187-220.
26. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Off-spring cohort. Am J Clin Nutr. 2001;73:613-621.
27. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. JAMA. 1995;274:1526-1533.
28. Whincup PH, Refsum H, Perry IJ, et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart. 1999;82:448-454.
29. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000;101:2118-2121.
30. The PHREG Procedure. Changes and enhancements, through release 6.12. Cary, NC: SAS Institute, Inc; 1997.
31. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20:421-428.
32. Chao CL, Tsai HH, Lee CM, et al. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis. 1999;147:379-386.
33. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050.
34. Lentz SR. Homocysteine and vascular dysfunction. Life Sci. 1997;61:1205-1215.
35. Chilian WM. Coronary microcirculation in health and disease. Circulation. 1997;95:522-528.
36. Symons JD, Mullick AE, Ensunsa JL, Ma AA, Rutledge JC. Hyperhomocysteinemia evoked by folate depletion. Arterioscler Thromb Vasc Biol. 2002;22:772-780.
37. Al Obaidi MK, Stubbs PJ, Collinson P, Conroy R, Graham I, Noble MI. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J Am Coll Cardiol. 2000;36:1217-1222.
38. Nurk E, Tell GS, Nygard O, Refsum H, Ueland PM, Vollset SE. Plasma total homocysteine is influenced by prandial status in humans: the Hordaland Homocysteine Study. J Nutr. 2001;131:1214-1216.
39. Clarke R, Lewington S, Donald A, et al. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk. 2001;8:363-369.
40. Food standards: amendment of standards of identity for enriched grain products to require additional folic acid. Fed Register. 1996;61:8781-8797.
41. Jacques PF, Selhub, J, Boston AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.